vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and Verisign (VRSN). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $425.3M, roughly 1.7× Verisign). Verisign runs the higher net margin — 48.5% vs 19.1%, a 29.4% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 7.6%). Verisign produced more free cash flow last quarter ($285.1M vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 5.2%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Verisign, Inc. is an American company based in Reston, Virginia, that operates a diverse array of network infrastructure, including two of the Internet's thirteen root nameservers, the authoritative registry for the .com, .net, and .name generic top-level domains and the .cc country-code top-level domains, and the back-end systems for the .jobs and .edu sponsored top-level domains.
MEDP vs VRSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $425.3M |
| Net Profit | $135.1M | $206.2M |
| Gross Margin | — | 88.5% |
| Operating Margin | 21.6% | 67.0% |
| Net Margin | 19.1% | 48.5% |
| Revenue YoY | 32.0% | 7.6% |
| Net Profit YoY | 15.5% | 7.7% |
| EPS (diluted) | $4.65 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $425.3M | ||
| Q3 25 | $659.9M | $419.1M | ||
| Q2 25 | $603.3M | $409.9M | ||
| Q1 25 | $558.6M | $402.3M | ||
| Q4 24 | $536.6M | $395.4M | ||
| Q3 24 | $533.3M | $390.6M | ||
| Q2 24 | $528.1M | $387.1M | ||
| Q1 24 | $511.0M | $384.3M |
| Q4 25 | $135.1M | $206.2M | ||
| Q3 25 | $111.1M | $212.8M | ||
| Q2 25 | $90.3M | $207.4M | ||
| Q1 25 | $114.6M | $199.3M | ||
| Q4 24 | $117.0M | $191.5M | ||
| Q3 24 | $96.4M | $201.3M | ||
| Q2 24 | $88.4M | $198.8M | ||
| Q1 24 | $102.6M | $194.1M |
| Q4 25 | — | 88.5% | ||
| Q3 25 | — | 88.4% | ||
| Q2 25 | — | 88.0% | ||
| Q1 25 | — | 87.7% | ||
| Q4 24 | — | 87.8% | ||
| Q3 24 | — | 88.0% | ||
| Q2 24 | — | 87.8% | ||
| Q1 24 | — | 87.2% |
| Q4 25 | 21.6% | 67.0% | ||
| Q3 25 | 21.5% | 67.8% | ||
| Q2 25 | 20.9% | 68.5% | ||
| Q1 25 | 20.3% | 67.4% | ||
| Q4 24 | 23.4% | 66.7% | ||
| Q3 24 | 21.1% | 68.9% | ||
| Q2 24 | 19.9% | 68.8% | ||
| Q1 24 | 20.4% | 67.4% |
| Q4 25 | 19.1% | 48.5% | ||
| Q3 25 | 16.8% | 50.8% | ||
| Q2 25 | 15.0% | 50.6% | ||
| Q1 25 | 20.5% | 49.5% | ||
| Q4 24 | 21.8% | 48.4% | ||
| Q3 24 | 18.1% | 51.5% | ||
| Q2 24 | 16.7% | 51.4% | ||
| Q1 24 | 20.1% | 50.5% |
| Q4 25 | $4.65 | — | ||
| Q3 25 | $3.86 | — | ||
| Q2 25 | $3.10 | — | ||
| Q1 25 | $3.67 | — | ||
| Q4 24 | $3.67 | — | ||
| Q3 24 | $3.01 | — | ||
| Q2 24 | $2.75 | — | ||
| Q1 24 | $3.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $580.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $-2.2B |
| Total Assets | $2.0B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $580.5M | ||
| Q3 25 | $285.4M | $617.7M | ||
| Q2 25 | $46.3M | $593.8M | ||
| Q1 25 | $441.4M | $648.5M | ||
| Q4 24 | $669.4M | $599.9M | ||
| Q3 24 | $656.9M | $644.9M | ||
| Q2 24 | $510.9M | $689.9M | ||
| Q1 24 | $407.0M | $924.7M |
| Q4 25 | $459.1M | $-2.2B | ||
| Q3 25 | $293.6M | $-2.1B | ||
| Q2 25 | $172.4M | $-2.0B | ||
| Q1 25 | $593.6M | $-2.0B | ||
| Q4 24 | $825.5M | $-2.0B | ||
| Q3 24 | $881.4M | $-1.9B | ||
| Q2 24 | $763.6M | $-1.8B | ||
| Q1 24 | $671.5M | $-1.6B |
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $1.8B | $1.4B | ||
| Q2 25 | $1.6B | $1.4B | ||
| Q1 25 | $1.9B | $1.4B | ||
| Q4 24 | $2.1B | $1.4B | ||
| Q3 24 | $2.1B | $1.5B | ||
| Q2 24 | $1.9B | $1.5B | ||
| Q1 24 | $1.8B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $289.6M |
| Free Cash FlowOCF − Capex | $188.1M | $285.1M |
| FCF MarginFCF / Revenue | 26.6% | 67.0% |
| Capex IntensityCapex / Revenue | 0.6% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.43× | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $289.6M | ||
| Q3 25 | $246.2M | $307.7M | ||
| Q2 25 | $148.5M | $202.5M | ||
| Q1 25 | $125.8M | $291.3M | ||
| Q4 24 | $190.7M | $231.5M | ||
| Q3 24 | $149.1M | $253.4M | ||
| Q2 24 | $116.4M | $160.4M | ||
| Q1 24 | $152.7M | $257.3M |
| Q4 25 | $188.1M | $285.1M | ||
| Q3 25 | $235.5M | $303.0M | ||
| Q2 25 | $142.4M | $194.7M | ||
| Q1 25 | $115.8M | $285.5M | ||
| Q4 24 | $183.0M | $222.0M | ||
| Q3 24 | $138.5M | $247.8M | ||
| Q2 24 | $103.5M | $151.2M | ||
| Q1 24 | $147.2M | $253.5M |
| Q4 25 | 26.6% | 67.0% | ||
| Q3 25 | 35.7% | 72.3% | ||
| Q2 25 | 23.6% | 47.5% | ||
| Q1 25 | 20.7% | 71.0% | ||
| Q4 24 | 34.1% | 56.1% | ||
| Q3 24 | 26.0% | 63.4% | ||
| Q2 24 | 19.6% | 39.1% | ||
| Q1 24 | 28.8% | 66.0% |
| Q4 25 | 0.6% | 1.1% | ||
| Q3 25 | 1.6% | 1.1% | ||
| Q2 25 | 1.0% | 1.9% | ||
| Q1 25 | 1.8% | 1.4% | ||
| Q4 24 | 1.4% | 2.4% | ||
| Q3 24 | 2.0% | 1.4% | ||
| Q2 24 | 2.4% | 2.4% | ||
| Q1 24 | 1.1% | 1.0% |
| Q4 25 | 1.43× | 1.40× | ||
| Q3 25 | 2.22× | 1.45× | ||
| Q2 25 | 1.65× | 0.98× | ||
| Q1 25 | 1.10× | 1.46× | ||
| Q4 24 | 1.63× | 1.21× | ||
| Q3 24 | 1.55× | 1.26× | ||
| Q2 24 | 1.32× | 0.81× | ||
| Q1 24 | 1.49× | 1.33× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
VRSN
Segment breakdown not available.
